Pretransplantation mogamulizumab for ATLL raises risk of GVHDAugust 23, 2016Aggressive LymphomasT Cell Lymphomas
Bendamustine-based chemotherapy induces high CR rate in relapsed HLJuly 8, 2016Indolent LymphomaAggressive Lymphomas
Pembrolizumab shows signs of efficacy in relapsed/refractory classical Hodgkin lymphomaJuly 5, 2016Aggressive LymphomasHodgkin Lymphoma
‘Impressive’ responses with nivolumab in relapsed Hodgkin lymphomaJune 16, 2016Aggressive LymphomasHodgkin Lymphoma
Daratumumab plus len-dex stalls myeloma progression in POLLUX trialJune 15, 2016Multiple MyelomaAggressive Lymphomas
Follicular lymphoma with histologic transformation may merit ASCTJune 14, 2016Indolent LymphomaAggressive Lymphomas
Mogamulizumab achieves objective responses in relapsed/refractory adult T-cell leukemia-lymphomaJune 10, 2016Aggressive LymphomasT Cell Lymphomas
Alemtuzumab plus CHOP didn’t boost survival in elderly patients with peripheral T-cell lymphomasJune 10, 2016T Cell LymphomasAggressive Lymphomas
FDA grants accelerated approval to nivolumab for Hodgkin lymphomaMay 17, 2016Aggressive LymphomasHodgkin Lymphoma
Epstein-Barr virus DNA in plasma reliably detects EBV-positive lymphoproliferative disordersMay 11, 2016Indolent LymphomaAggressive Lymphomas
Dose-escalated blinatumomab plus dexamethasone induced responses in relapsed/refractory DLBCLApril 22, 2016Aggressive Lymphomas
FDG-PET guides need for eBEACOPP in advanced Hodgkin’sApril 12, 2016Indolent LymphomaAggressive LymphomasHodgkin Lymphoma
